8-K: Cencora Reports Strong Q1, Raises Operating Income Guidance

Cencora announced robust fiscal Q1 2026 results with revenue up 5.5% to $85.9 billion and raised its adjusted operating income guidance for the full fiscal year.

Summary

• Fiscal Q1 2026 revenue increased 5.5% year-over-year to $85.9 billion.
• GAAP diluted EPS for Q1 2026 was $2.87, up 14.8% from $2.50 in the prior year.
• Adjusted diluted EPS for Q1 2026 increased 9.4% to $4.08 from $3.73 in the prior year.
• Adjusted operating income guidance for fiscal year 2026 was raised to growth of 11.5% to 13.5% (from 8% to 10%).
• The company completed the acquisition of a majority interest in OneOncology for approximately $4.6 billion, funded through new debt financing.
• U.S. Healthcare Solutions segment revenue grew 5.0% to $76.2 billion, driven by market growth, specialty products, and GLP-1 class drugs, partially offset by customer losses.
• International Healthcare Solutions segment revenue grew 9.6% to $7.6 billion, primarily due to European distribution business growth, but operating income decreased by 13.9%.
• Operating expenses increased 24.8% to $2.3 billion, primarily due to the January 2025 acquisition of Retina Consultants of America (RCA) and a $249.5 million impairment of assets related to its U.S. Consulting Services business held for sale.
• Net interest expense increased by $44.5 million to $72.4 million, primarily due to new debt financing for the RCA acquisition.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, driven by robust financial performance, a significant strategic acquisition, and an upward revision of key guidance metrics, despite increased debt and some segment-specific challenges.

Positives

• Strong revenue growth of 5.5% year-over-year, reaching $85.9 billion.
• GAAP diluted EPS increased 14.8% to $2.87.
• Adjusted diluted EPS increased 9.4% to $4.08.
• Adjusted operating income guidance for fiscal year 2026 was raised from 8-10% growth to 11.5-13.5% growth.
• Successful completion of the OneOncology acquisition, strengthening the specialty MSO footprint and cancer care partnerships.
• U.S. Healthcare Solutions segment revenue increased 5.0% and operating income increased 21.0%.
• International Healthcare Solutions segment revenue increased 9.6%.
• A litigation and opioid-related credit of $86.8 million was recognized.

Negatives

• Operating expenses increased significantly by 24.8% to $2.3 billion, partly due to the RCA acquisition and a $249.5 million asset impairment.
• International Healthcare Solutions segment operating income decreased by 13.9% (17.0% on a constant currency basis).
• Net interest expense increased by $44.5 million to $72.4 million due to new debt financing.
• Losses of a grocery customer and an oncology customer in the U.S. Healthcare Solutions segment.
• Lower operating income at consulting services businesses due to the loss of a manufacturer customer program.
• Cash and cash equivalents decreased from $4,356,138 thousand at September 30, 2025, to $1,753,122 thousand at December 31, 2025.

Risks

• Actual results could differ materially from forward-looking statements due to risks and uncertainties discussed in the company's Annual Report on Form 10-K and other SEC filings.
• LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the company's control.
• Acquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.
• The timing and amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable and cannot be reasonably estimated.

Future Outlook

Cencora updated its fiscal year 2026 financial guidance, raising adjusted operating income growth to 11.5% to 13.5% from the previous 8% to 10%, primarily reflecting the OneOncology acquisition and strong U.S. Healthcare Solutions segment performance. The company reaffirmed its full fiscal 2026 adjusted diluted EPS guidance range at $17.45 to $17.75. Future net interest expense is projected to be $480M to $500M, and adjusted free cash flow is expected to be around $3.0 billion.

Management Comments

• "Cencora began fiscal 2026 by delivering strong financial performance and advancing our strategy through the acquisition of OneOncology."
• "Our ownership of OneOncology cements our specialty MSO footprint and deepens our partnership with physicians leading in cancer care."
• "As we continue to advance our leadership in specialty and execute our pharmaceutical-centric strategy, we are well positioned to drive continued value for all our stakeholders and deliver on our purpose."

Industry Context

StockSavvy.ai notes that Cencora's strategic acquisition of OneOncology aligns with a broader industry trend of pharmaceutical distributors and healthcare solution providers integrating further into specialized care delivery, particularly in high-growth areas like oncology. This move enhances Cencora's position in the specialty MSO market, a segment seeing increased consolidation and vertical integration as companies seek to control more of the value chain and deepen relationships with care providers. The strong performance in U.S. Healthcare Solutions, partly driven by GLP-1 class drugs, highlights the significant impact of new therapeutic categories on the pharmaceutical distribution landscape.

Comparison to Industry Standards

• Cencora's 5.5% revenue growth to $85.9 billion in Q1 2026 is competitive within the pharmaceutical distribution sector, which typically sees steady, single-digit growth driven by drug price inflation and volume. Major competitors like Cardinal Health and McKesson also report substantial revenues, with growth rates varying based on market dynamics and strategic acquisitions.
• The 9.4% increase in adjusted diluted EPS to $4.08 demonstrates strong profitability growth, potentially outpacing some peers who might face tighter margins or higher operational costs. The raised adjusted operating income guidance suggests management confidence in sustained performance, a positive signal compared to companies maintaining or lowering guidance in uncertain economic environments.
• The acquisition of OneOncology for $4.6 billion is a significant strategic investment, comparable in scale to other large M&A activities seen in the healthcare services and specialty pharmacy space, where companies are building integrated platforms to offer comprehensive solutions from drug distribution to patient care management.

Legal Proceedings

• The company recognized an $86.8 million credit related to a derivative lawsuit settlement in Q1 2026.
• The company previously had litigation and opioid-related expenses in the prior year quarter.
• Gains from antitrust litigation settlements are excluded from non-GAAP measures, relating to lawsuits against brand pharmaceutical manufacturers.

Stakeholder Impact

• Shareholders: Positive impact from increased EPS, raised operating income guidance, and a declared quarterly dividend of $0.60 per share.
• Physicians/Oncology Practices: Deepened partnership and support through the OneOncology acquisition, enhancing the physician-led national platform.
• Customers: Continued secure, reliable delivery of pharmaceuticals and healthcare products. Potential impact from loss of a grocery and an oncology customer.
• Creditors: Increased debt financing for acquisitions, leading to higher interest expense.

Next Steps

• Conference call and webcast on February 4, 2026, at 8:30 a.m. ET to discuss results and related matters.
• Management will attend the Leerink Partners Global Healthcare Conference from March 8-11, 2026.
• Management will attend the Barclays Global Healthcare Conference from March 10-12, 2026.
• Quarterly cash dividend of $0.60 per common share payable March 2, 2026, to stockholders of record on February 13, 2026.

Key Dates

Recommendation

The company delivered strong Q1 results with significant revenue and EPS growth, coupled with a strategic acquisition that expands its footprint in a high-growth specialty area. The upward revision of full-year adjusted operating income guidance signals robust future performance and management confidence. While debt increased, the strategic benefits and strong operational execution outweigh this, making it an attractive investment.

Keywords

Cencora, COR, Q1 2026 Earnings, Healthcare Solutions, Pharmaceutical Distribution, OneOncology Acquisition, Adjusted EPS, Operating Income Guidance, Specialty MSO, Oncology Care, GLP-1 drugs, SEC Filing